Beijing Memorial Pharmaceutical Research and Development Co.,Ltd.
+86 15810288723
Lang. :
English
中 文
☰
Home
Main Business
International Purchasement of Comparator
Exportation of R&D Drugs
Comparator Import & Export
Storage and Logistics of Investigational Product
Repackage of The Investigational Product
Clinical Trial Subjects Recruitment
R&D Products
News
Latest News
NDA News
Clinical News
Industrial News
Company Update
About Us
About CliniExpert
Big Events
Photo Wall
Clinical Viewpoint
Talent Recruitment
Home
News
· R&D Products
Olmesartan Medoxomil and Hydrochlorothiazide Tablets
CliniExpert
•
2019/12/20
119
•
0
奥美沙坦酯氢氯噻嗪片
Return
Hot Info
FDA Approves Daybue (trofinetide) for the Treatment of Rett Syndrome
FDA Approves Zavzpret (zavegepant) Nasal Spray for the Acute Treatment of Migraine
FDA Approves Altuviiio ([Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]) Once-Weekly VIII Therapy for Hemophilia A
FDA Grants Accelerated Approval to Filspari (sparsentan) for the Reduction of Proteinuria in IgA Nephropathy
FDA Approves Skyclarys (omaveloxolone) for the Treatment of Friedreich’s Ataxia
FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade
FDA Approves Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the Treatment of H. pylori Infection in Adults
FDA Approves Ziextenzo (pegfilgrastim-bmez), a Biosimilar to Neulasta
FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
FDA Approves Brukinsa (zanubrutinib) for the Treatment of Mantle Cell Lymphoma
PellePharm Completes Enrollment Of Pivotal Phase 3 Clinical Trial Of Patidegib Topical Gel In Patients With Gorlin Syndrome
Positive Phase III Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in the New England Journal of Medicine
The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing
New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths
Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors
15810288723
